Anti-HAF/SART1 Antibody, clone 1-2

U4/U6.U5 tri-snRNP-associated protein 1 (UniProt O43290; also known as Allergen Hom s 1, HAF, hSART-1, hSnu66, Hypoxia-associated factor, SART-1, SNU66 homolog, Squamous cell carcinoma antigen recognized by T-cells 1, U4/U6.U5 tri-snRNP-associated 110 kDa protein) is encoded by the SART1 (also known as HAF) gene (Gene ID 9092) in human. The hypoxia-associated factor (HAF) is an E3 ubiquitin ligase that mediates the ubiquitination and degradation of hypoxia-inducible factor 1α (HIF-1α). HAF also binds to HIF-2α and promotes HIF-2 transactivation instead of promoting HIF-2α degradation. In addition, hypoxia-dependent HAF SUMOylation enhances HAF interaction with HIF-2α and induction of HIF-2 target genes transcription, such as OCT-3/4, SOX2 and NANOG. HAF therefore promotes stem cell characteristics, aggressive tumor growth and invasion by switching cells from HIF-1α- to HIF-2α-dependent signaling. HAF overexpression enhances glioblastoma cells that express both HIF-1α and HIF-2α to initiate tumors as intracranial xenografts in mice. On the other hand, HAF overexpression results in decreased xenograft tumor growth of HT29 colon carcinoma cells that only express HIF-1α.

~110 kDa observed. 90.26 kDa calculated. The larger-than-calculated target band size is consistent with that reported in the literature (Koh, M.Y. et al. (2015). Cancer Res. 75(2):316-329). Uncharacterized bands may be observed in some lysate(s).

GST-tagged recombinant human HAF/SART1 C-terminal fragment.

Detect HAF/SART1 using this mouse monoclonal Anti-HAF/SART1, clone 1-2 Antibody, Cat. No. MABC1149, validated for use in Western Blotting and Immunocytochemistry, Immunohistochemistry, and Western Blotting.

Immunocytochemistry Analysis: A 1:200 dilution from a representative lot detected HAF/SART1 in A431 cells.

Western Blotting Analysis: A 1:62.5 dilution from a representative lot detected HAF/SART1 in 10 µg of Jurkat cell lysate.

Immunocytochemistry Analysis: A representative lot detected a reduced HAF immunoreactivity in MIA PaCa-2 human pancreatic carcinoma cells following HAF shRNA treatment (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).

Immunocytochemistry Analysis: A representative lot detected HAF in HeLa and PANC-1 cells (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).

Immunocytochemistry Analysis: A representative lot detected an increased HAF immunoreactivity in 786-O human kidney cancer cells transfected to overexpress HAF (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).

Immunohistochemistry Analysis: A representative lot detected HAF immunoreactivity in 786-O xenograft (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).

Research Category
Apoptosis & Cancer

Clone 1-2 detected HAF shRNA-mediated HAF knockdown in MIA PaCa-2 human pancreatic carcinoma cells.

Format: Purified

Protein G purified.

Purified mouse IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide

Stable for 1 year at 2-8°C from date of receipt.

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:62.5 dilution from a representative lot detected HAF/SART1 in 10 µg of HeLa cell lysate.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.